FDx Advisors’s Cellectis CLLS Stock Holding History

FDx Advisors’s Portfolio CLLS Stock Details CLLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-8,653	Closed	-$234K	–	773
2020 Q4	$234K	Buy	+8,653	New	+$194K	0.01%	641

Other funds holding CLLS

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

CII

Capital International Inc Los Angeles, California $13B AUM 31.88% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Bpifrance Maisons Alfort, Cedex, France $1.65B AUM 19.85% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

CIA

Capital Impact Advisors Boston, Massachusetts $247M AUM 31.15% 1-Year Est. Return

FDx Advisors's CLLS Position: Q1 2021 in Review

FDx Advisors sold out of Cellectis (CLLS) in Q1 2021, closing a stake of 8,653 shares — an estimated $234K sold.

FDx Advisors first reported a position in CLLS in Q4 2020 and held it in 1 quarter. The position peaked at $234K in Q4 2020. 81 funds tracked by Wall St. Rank hold CLLS as of Q1 2021.

FDx Advisors reported no remaining Cellectis position as of Q1 2021 after selling out during the quarter.
FDx Advisors sold 8,653 Cellectis shares in Q1 2021, an estimated $234K.
FDx Advisors first reported a position in Cellectis in Q4 2020 and held it in 1 quarter.
FDx Advisors's Cellectis position peaked at $234K in Q4 2020.
81 funds tracked by Wall St. Rank held Cellectis as of Q1 2021.

Based on FDx Advisors's 13F filing for Q1 2021, filed 13 Apr 2021.